| Gene symbol | E2F1 | Synonyms | E2F-1, RBAP1, RBBP3, RBP3 | Type of gene | protein-coding |
| Chromosome | 20 | Map location | 20q11.22 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | E2F transcription factor 1 | ||||
| Gene symbol | SPAM1 | Synonyms | HEL-S-96n, HYA1, HYAL1, HYAL3, HYAL5, PH-20, PH20, SPAG15 | Type of gene | protein-coding |
| Chromosome | 7 | Map location | 7q31.32 | dbXrefs | |
| Description | sperm adhesion molecule 1 | ||||
| GTO ID | GTC3982 |
| Trial ID | NCT02045602 |
| Disease | Solid Tumor | Pancreatic Adenocarcinoma |
| Altered gene | E2F1|PH20 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | VCN-01 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors |
| Year | 2014 |
| Country | Spain |
| Company sponsor | Theriva Biologics SL |
| Other ID(s) | P-VCNA-001|2012-005555-16 |
| Vector information | |||||||||||||
|
|||||||||||||
| Cohort1: VCN-01 | |||||||
|
|||||||
| Cohort2: VCN-01_Gemcitabine_Abraxane | |||||||
|
|||||||